Synergisic effects of terbinafine combined with fluconazole or itraconazole on stable fluconazole-resistant Candida albicans induced by fluconazole in vitro

Chinese Journal of Microbiology and Immunology

Volumn 26, Issue 4, 2006, Pages 360-364

  Jiang, Wei Su ^a   Tan, Sheng Shun ^a   Jiang, Guo Ying ^a   Chen, Qing Xui ^a  

^a THE SECOND AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Candida albicans; Fluconazole; Itraconazole; Terbinafine

Indexed keywords

FLUCONAZOLE; ITRACONAZOLE; TERBINAFINE;

ARTICLE; CANDIDA ALBICANS; IN VITRO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE;

EID: 33746086078     PISSN: 02545101     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Czaika V, Tietz HJ, Schmalreck A, et al. Antifungal susceptibility testing in chronically recurrent vaginal candidiasis as basis for effective therapy. Mycoses, 2000, 43(suppl 2): 45-50.
2. Evans EC. Resistance of Candida species to antifungal agent used in the treatment of onychomycosis: a review of current problems. Br J Dermatol, 1999, 141(Suppl 56): 33-35.
3. Mosquera J, Sharp A, Moore CB, et al. In vitro interaction of terbinafine with itraconazole, fluconazole, amphotericin B and 5-flucytosine against Aspergillus spp. J Antimicrob Chemother, 2002, 50(2): 189-194.
4. Te Dorsthorst DT, Verweij PE, Meis JF, et al. Comparison of fractional inhibitory concentration index with response surface modeling for characterization of in vitro interaction of antifungals against itraconazole-susceptible and -resistant Aspergillus fumigatus isolates. Antimicrob Agents Chemother, 2002, 46(3): 702-707.
5. Weig M, Muller FM. Synergism of voriconazole and terbinafine against Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob Agents Chemother, 2001, 45(3): 966-968.
6. Ghannoum MA, Elewski B. Successful treatment of fluconazole-resistant oropharyngeal candidiasis by a combination of fluconazole and terbinafine. Clin Diagn Lab Immunol, 1999, 6(6): 921-923.
7. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts; Approved Standard M27-a Villanova. NCCLS, 1997, 17(9): XV.
8. Cowen LE, Sanglard D, Calabrese D, et al. Evolution of drug resistance in experimental populations of Candida albicans. Antimicrob Agents Chemother, 2000, 182(6): 1515-1522.
9. Mosquera J, Sharp A, Moore CB, et al. In vitro interaction of terbinafine with itraconazole, fluconazole, amphotericin B and 5-flucytosine against Aspergillus spp. J Antimicrob Chemother, 2002, 50(2): 189-194.
10. Perea S, Gonzalez C, Annette W, et al. In vitro activities of terbinafine in combination with fluconazole, itraconazole, voriconazole, and posaconazole against clinical isolates of Candida glabrata with decreased susceptibility to azole. J Clin Microbiol, 2002, 40(5): 1831-1833.
11. Chartier FL, Keer JT, Sutcliffe MJ, et al. Construction of a mouse yeast artificial chromosome library in a recombination-deficient strain of yeast. Nat Genet, 1992, 1(2): 132-136.
12. Lai MH, Kirsch DR. Nucleotide sequence of cytochrome P450 L1A1 (lano-sterol 14 alpha-demethylase) from Candida albicans. Nucleic Acids Res, 1989, 17(2): 804.
13. Sanglard D, Ischer F, Koymans L, et al. Amino acid substitutions in the cytochrome P-450 lanosterol 14 alpha-demethylase (CYP51A) own azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob Agents Chemother, 1998, 42(2): 241-253.
14. White TC. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a HIV-infected patient. Antimicrob Agents Chemother, 1997, 41(7): 1482-1487.
15. Sanglard D, Ischer F, Koymans L, et al. Amino acid substitutions in the cytochrome P-450 lanosterol 14 alpha-demethylase (CYP51A) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob Agents Chemother, 1998, 42(2): 241-253.
16. Franz R, Kelly SL, Lamb DC, et al. Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains. Antimicrob Agents Chemother, 1998, 42(12): 3065-3072.
17. Perea S, Lopez-Ribot JL, Kirkpatrick WR, et al. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother, 2001, 45(10): 2676-2684.